ZheJiang Tailin Bioengineering Co., Ltd. Class A

ZheJiang Tailin Bioengineering Co., Ltd. Class A

SSZSE:300813
18.09
CNY
-0.54
(-2.90%)
0.25EPS
92.46P/E
2.77BMarket Cap
ZheJiang Tailin Bioengineering Co., Ltd. Class A
SZSE:300813
(Shenzhen Stock Exchange)

Recent

price

18.09

P/E

ratio

92.46

div

yld

0.55%

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
4.5
2.83
1.11
1.37
1.75
1.97
2.22
1.89
2.61
3.47
2.47
3.21
2.88
3.16
Revenue per Share
1.02
0.48
0.21
0.36
0.55
0.6
0.42
0.46
0.58
0.74
0.18
0.12
0.14
0.25
Basic EPS, GAAP
0.44
0.78
0.3
0.21
-0.04
-0.06
0.08
0.94
0.09
0.56
-1.6
0.06
0.01
- -
Free Cash Flow per Basic Share
- -
0.57
0.11
0.12
0.19
- -
- -
0.29
0.09
0.17
0.25
0.1
0.21
0.1
Dividend per Share
3.09
2.62
1.2
1.43
1.81
2.4
2.83
4.11
4.6
5.99
5.97
6.77
6.64
6.65
Book Value per Share
2.97
2.5
1.17
1.28
1.65
2.25
2.68
4
4.49
5.88
5.86
6.68
6.41
6.43
Tangible Book Value per Share
21
21
74
82
81
81
81
106
109
108
109
109
118
121
Basic Weighted Avg Shares
94
59
82
112
142
159
181
200
283
374
270
349
340
381
Sales/Revenue/Turnover
23.62
10.9
14.98
23.25
32.61
34.14
21.16
23.24
22.42
18.6
4.6
5.1
4.03
7.91
Operating Margin (%)
1
2
2
3
3
3
8
8
8
13
11
17
17
- -
Depreciation Expense
21
10
15
29
45
48
34
48
64
80
20
13
16
30
Net Income, GAAP
11.78
12.39
12.02
12.34
13.04
10.22
10.69
6.46
8.78
0.33
16.07
4.02
2.7
6.32
Effective Tax Rate (%)
22.71
17.01
18.67
25.96
31.68
30.31
19.02
24.16
22.43
21.31
7.29
3.74
4.86
7.83
Profit Margin (%)
33
24
67
76
85
81
113
330
361
634
477
497
398
392
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
4
145
158
- -
- -
- -
LT Debt
65
55
97
116
146
195
229
444
497
647
650
821
804
806
Total Equity
- -
9.54
13.67
21.38
28.19
26.08
15.9
14.24
13.28
12.17
2.27
1.46
2.03
- -
Return on Invested Capital (%)
- -
16.88
20.17
27.15
31.87
26.5
16.26
14.35
13.41
12.42
2.67
3.44
3.81
- -
Return on Capital (%)
- -
16.88
20.17
27.15
34.24
28.26
16.24
14.37
13.49
13.92
3.03
1.78
2.03
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
121
121
121
Market Capitalization
3,511
2,314
2,767

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
552
524
546
Cash, Cash Equivalents & STI
229
193
208
Accounts Receivable, Net
47
55
47
Inventories
133
136
144
Total Current Liabilities
138
145
154
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.66%
13.36%
-2%
Free Cash Flow
88.35%
-33.94%
-86.33%
Net Income, GAAP
13.7%
-5.18%
26.32%
Sales/Revenue/Turnover
17.15%
14.45%
-2.71%
Total Cash Common Dividend
- -
25.44%
120.51%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
80
76
86
107
349
2025
67
79
- -
126
340
2026
70
95
90
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.01
0.04
0.01
0.12
2025
0.03
0.08
- -
0.01
0.14
2026
0.04
0.13
0.06
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.1
2025
- -
- -
- -
- -
0.21
2026
- -
- -
0.1
- -
- -
Business
Zhejiang Tailin BioEngineering Co.,Ltd (300813.SZ), founded in 2002 and headquartered in Hangzhou, China, provides integrated life science system solutions focused on microbial detection, contamination control, aseptic isolation, and analytical instrumentation for the biopharmaceutical, medical, biosafety, food, environmental, and electronics industries. The company manufactures and sells core products including sterility testing systems such as bacteria collectors, sterility test pumps, and single-closed sterile canisters; aseptic isolators and negative isolators for cell and gene therapy (ATMPs) and radiopharmaceuticals; VHPS vapor hydrogen peroxide decontamination and biodecontamination systems; glove integrity testers and leak detectors; total organic carbon (TOC) analyzers with dual-wave UV oxidation; filter integrity testers and membrane filtration systems; microbial limit testing systems with reusable filters; dissolution testers; shakers; and related consumables and technical services including validation, installation, and qualification support. Tailin operates subsidiaries covering microbiological analysis, medical engineering for biosafety and isolation, analytical instruments, and international business, with products serving customers in over 40 countries and holding more than 300 patents while contributing to national standards and the Chinese Pharmacopoeia. In recent developments, the company advances its globalization strategy through participation in major 2025 exhibitions including CPHI&PMEC China (June), Maghreb Pharma Expo in Algeria (April), and MIECF in Macao (March), following 2024 events at CPHI Milan, CPHI SEA in Thailand, and FILTECH in Germany that strengthened Southeast Asian and European market ties; Tailin also hosted a successful 2024 Open Day for international customers and continues industrialization of cell and gene therapy isolator workstations with nine related patents.